Table I.
Characteristics of participating CCS in the discovery and two replication cohorts.
| Discovery DCOG LATER-VEVO (n = 285) | Replication PanCareLIFE (n = 465) | Replication St. Jude Lifetime (n = 391) | |
|---|---|---|---|
| Age at time of study (years) | |||
| Median (range) | 26.1 (18.3–52.4) | 25.7 (18.0–45.0) | 31.3 (19.1–59.5) |
| Age at diagnosis (years) | |||
| Median (range) | 5.8 (0.3–17.8) | 10.4 (0.0–25.0) | 6.9 (0.0–22.7) |
| 18–25 years | 0 (0) | 21 (4.5) | 16 (4.1) |
| Time since diagnosis (years) | |||
| Median (range) | 19.7 (6.7–41.4) | 17.0 (5.0–39.1) | 23.7 (11.0–46.2) |
| Diagnosis | |||
| Leukaemia | 112 (39.3) | 109 (23.4) | 121 (30.9) |
| Lymphoma | 49 (17.2) | 154 (33.1) | 70 (17.9) |
| Renal tumors | 37 (13.0) | 35 (7.5) | 27 (6.9) |
| CNS tumors | 3 (1.1) | 12 (2.6) | 28 (7.2) |
| Soft tissue sarcoma | 23 (8.1) | 31 (6.7) | 28 (7.2) |
| Bone tumors | 26 (9.1) | 45 (9.7) | 34 (8.7) |
| Neuroblastoma | 11 (3.9) | 35 (7.4) | 36 (9.2) |
| Other | 24 (8.4) | 44 (9.6) | 47 (12.0) |
| Radiotherapy | |||
| No | 251 (88.1) | 297 (63.9) | 268 (68.5) |
| Yesa | 34 (11.9) | 170 (36.1) | 123 (31.5) |
| Thorax | 22 (7.7) | 88 (18.9) | 71 (18.2) |
| Abdomen (above pelvic crest) | 3 (1.1) | 12 (2.6) | 30 (7.7) |
| Unilateral ovarianb | 0 (0) | 9 (1.9) | 3 (0.8) |
| Other | 20 (7.0) | 61 (13.1) | 51 (13.0) |
| CED score | |||
| 0 | 106 (37.2) | 161 (34.6) | 198 (50.6) |
| >0–4000 mg/m2 | 80 (28.1) | 103 (22.2) | 21 (5.4) |
| ≥4000–8000 mg/m2 | 52 (18.2) | 68 (14.9) | 78 (19.9) |
| ≥8000 mg/m2 | 47 (16.5) | 133 (28.6) | 94 (24.0) |
| Hormone use at serum sampling | |||
| No | 199 (69.9) | 232 (49.9) | 263 (67.3) |
| Yes | 86 (30.1) | 116 (24.9) | 128 (32.7) |
| Oral contraceptive-free day 7 | 70 (24.6) | 3 (0.6) | NA |
| Anytime during oral contraceptive | NA | 94 (20.2) | NA |
| HRT stop 7 | 2 (0.7) | 20 (4.3) | NA |
| Anytime, with intrauterine device | 14 (4.9) | NA | NA |
| Unknown | 0 (0) | 117 (25.2) | 0 (0) |
| Unilateral ovarian oophorectomy | |||
| No | 284 (99.6) | 463 (99.6) | 391 (100.0) |
| Yes | 1 (0.4) | 2 (0.4) | 0 (0) |
| AMH level | |||
| Median (range) | 2.5 (<0.01–13.1) | 2.1 (<0.01–18.5) | 1.8 (<0.01–11.9) |
| Premature menopause (before age 40) and aged ≥40 years at study, | 2 (0.7) | NA | 4 (1.0) |
Values are represented as the number (%) of women, unless indicated otherwise.
a
Not mutually exclusive.
b
Likely in radiotherapy field.
AMH, anti-Müllerian hormone in µg/l; CCS, childhood cancer survivors; CED, cyclophosphamide equivalent dose; CNS, central nervous system; DCOG LATER-VEVO, Dutch Childhood Oncology Group (DCOG) LATER VEVO cohort; HRT, hormonal replacement therapy; NA, not available; PanCareLIFE, PanCareLIFE cohort; St. Jude Lifetime, St. Jude Lifetime Cohort.